|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Altogether, our data show that in a tumor environment BMP9 and BMP10 play different roles and thus blocking their shared receptor ALK1 is maybe not appropriate.
|
30165893 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models.
|
28031424 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In order to study the effect of BMP9 <i>in vitro</i> and <i>in vivo</i> on cancer cells and tumor growth, we used a soluble chimeric protein consisting of the ALK1 extracellular domain (ECD) fused to human Fc (ALK1Fc) that prevents binding of BMP9 to its cell surface receptors and thereby blocks its ability to activate downstream signaling.
|
29259971 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An immunohistochemical analysis of the tumor samples revealed that ALK1-Fc treatment increased the pericyte coverage of the remaining tumor vessels and decreased the hypoxia within the tumor.
|
26373572 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TGF-β signaling is modulated by the coreceptor Endoglin (Eng), which shows a tumor suppressor activity in epithelial cells and regulates the ALK1-Smad1,5,8 as well as the ALK5-Smad2,3 signaling pathways.
|
24618373 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A high level of ACVRL1 expression in tumor tissue is significantly correlated with advanced T classification, positive N classification, advanced TNM stage, and poorer prognosis.
|
23447486 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patient less than 23 years, ALK-1 positivity and unifocal tumor may be associated with a better prognosis.
|
23923083 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because the skin may be the site of a wide variety of hematolymphoid and fibroblastic proliferations, dermatopathologists commonly use ALK1 as part of a broader staining panel in diagnosing soft tissue and cutaneous hematolymphoid neoplasms.
|
23689691 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Case 2 was that of a 34-year-old woman with an exophytic tumor (Alk-1+).CGH revealed losses on 13q14-22.
|
19787794 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Diminution of ALK1 gene dosage or systemic treatment with the ALK1-Fc fusion protein RAP-041 retarded tumor growth and progression by inhibition of angiogenesis in a transgenic mouse model of multistep tumorigenesis.
|
20065063 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, the authors investigated the expression of activin receptor-like kinase 1 (ALK1) in pancreatic carcinoma and evaluated its potential role as a tumor suppressor in vitro and in vivo.
|
17230504 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One patient with a gonadotroph tumor had a confirmed A482V germline mutation in the Alk1 gene within kinase subdomains X-XI.
|
10323406 |
1999 |